Healthcare, Regulatory and Reimbursement Landscape - Australia
GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Australia". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Australia. It identifies key trends, and most importantly, provides valuable insights into the trends and segmentation of the pharmaceutical and medical devices market. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts.
In 2010, Australia's population was 22.4 million, largely due to a positive balance between the birth rate and mortality rate and net overseas immigration. The mortality rate is almost steady due to Australia's strong healthcare infrastructure and medical and diagnostic services. The pharmaceutical market was estimated at $14.9 billion in 2010 and is expected to reach $30.5 billion by 2020 at a projected CAGR of 7.4%. The medical device market size was worth approximately $6.5 billion in 2011 and is expected to reach $10 billion by 2020 at a projected CAGR of 4.8%.
The positive trends in the healthcare market can be attributed primarily to -
Easy market access to pharmaceutical drugs
Increasing awareness of the need for the early detection of lifestyle and chronic diseases
Government-subsidized prescription medicines through the Pharmaceutical Benefit Scheme (PBS) for all eligible, general or concessional patients
Annual review and addition of expensive innovative drugs to the PBS drug list
The report provides information on the Australian healthcare, regulatory and reimbursement landscape, and includes -
Overview of the pharmaceutical and medical devices market, including size, segmentation, and key drivers and barriers.
Profiles and SWOT analyses of the major players in the pharmaceutical and medical devices market. The key players covered for the pharmaceutical market are Pfizer, AstraZeneca, Novartis, Sanofi and GlaxoSmithKline, and the key players covered for the medical devices market are Siemens Healthcare, GE Healthcare, DePuy Inc, F. Hoffmann-la Roche and Stryker Corporation.
Insightful review of the reimbursement and regulatory landscape, with details of the healthcare reimbursement process, regulatory agencies and market authorization processes for new drug and medical devices.
Detailed analysis of Australia's political and economic environment, including the economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
An overview of the opportunities for and challenges to growth in the healthcare market.
Reasons to buy
This report comprehensively covers both the pharmaceutical and the medical devices market in Australia. It will enhance your decision-making capability and allow you to -
Develop business strategies by understanding the trends shaping and driving the healthcare market.
Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments and companies likely to impact the healthcare market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnerships.
Identify, understand and capitalize on the opportunities and challenges in the healthcare market.
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 Report Guidance 10
3 Overview of the Pharmaceutical and Medical Device Market 11
3.1 Pharmaceutical Market 11
3.1.1 Supply Channels 14
3.1.2 Market Segments 16
3.1.3 Major Disease Areas 19
3.1.4 Major Players 21
3.2 Medical Device Market 49
3.2.1 Market Overview 49
3.2.2 Overview of the Top Five Segments 52
3.2.3 Major Players 63
3.3 Market Drivers and Barriers 80
3.3.1 Drivers 80
3.3.2 Barriers 81
4 Market Access 82
4.1 Reimbursement and Payers Landscape 82
4.1.1 Reimbursement Process 82
4.1.2 Overview of Insurance Providers 84
4.1.3 Patient Share in Healthcare Spending 87
4.1.4 Drug Price Trend 88
4.1.5 Pricing Policies 88
4.2 Regulatory Landscape 89
4.2.1 Overview of Regulatory Agencies 89
4.2.2 New Drug Approval Process 91
4.2.3 New Medical Device Approval Process 94
4.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing 98
4.2.5 Licensing Process for Pharmaceutical Exports and Imports 99
4.2.6 Intellectual Property Rights 100
4.2.7 Clinical Trial Regulations 101
4.2.8 Pharmaceutical and Medical Devices Advertising Regulations 102
4.2.9 Pharmacy Regulations 103
4.2.10 Labeling and Packaging Regulations 104
5 Country Analysis 105
5.1 Political Environment 105
5.1.1 Political Structure 105
5.1.2 Analysis of Current Political Environment 106
5.1.3 Healthcare Policy Initiatives 106
5.2 Economic Landscape 107
5.3 Economic Indicators 108
5.3.1 Gross Domestic Product 108
5.3.2 Gross National Income 111
5.3.3 Inflation 112
5.3.4 Currency Exchange Rate 115
5.3.5 Foreign Direct Investment 116
5.3.6 Foreign Exchange Reserves 117
5.3.7 Trade Balance 118
5.3.8 Government Structural Balance 120
5.3.9 Government Net Debt 121
5.3.10 Major Industries 123
5.4 Demography 124
5.4.1 Population 124
5.4.2 Education and Literacy 140
5.4.3 Employment 145
5.4.4 Disease Burden 146
5.4.5 Healthcare Facilities 148
5.4.6 Healthcare Parameters 154
5.4.7 Healthcare Personnel 156
5.4.8 Environmental Health 159
5.5 Healthcare Expenditure 162
5.5.1 Major Components of Healthcare Spending 163
5.5.2 Share of Public and Private Sector in Healthcare 164
5.5.3 Spending in Pharmaceutical R&D 165
5.6 Trade Associations 166
5.6.1 Australian Pharmaceutical Marketing and Research Group 166